From Blood Pressure Control to Weight-Centered Hypertension Management: The Emerging Role of Incretin-Based Therapies

Obesity and hypertension often coexist in the same person and reinforce each other. Treatment of hypertension in people with obesity has been based mainly on lifestyle changes and the gradual addition of antihypertensive drugs. The development of GLP-1 receptor agonists and combined GIP/GLP-1 agonists has transformed the treatment of obesity, with implications beyond weight loss. These therapies can produce significant weight loss, but they also lower blood pressure and improve several other cardiometabolic risk factors. Recent data suggest that the reduction in blood pressure is largely related to weight loss, but is not necessarily fully explained by it. Effects on natriuresis, endothelial function, inflammation, neurohormonal activity, and circulating volume may represent additional mechanisms. In practice, this creates a new situation: a patient who loses significant weight may need less antihypertensive therapy. Our aim is to examine the relationship between obesity and hypertension, the clinical evidence on semaglutide, tirzepatide, and newer incretin-based therapies, as well as the possible transition from an approach focused solely on blood pressure ​​toward management that also addresses adiposity as part of the disease mechanism.

Authors

Institutions

Publication Details

Journal
Acta Marisiensis. Seria Medica
Published
2026-11-17
DOI
https://doi.org/10.62838/amsm-2026-0037
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From Blood Pressure Control to Weight-Centered Hypertension Management: The Emerging Role of Incretin-Based Therapies

Margarita Gjata, Irida Kecaj, Ergita Nelaj, Kei Xixhabesi
2 links
Acta Marisiensis. Seria Medica
Blood Pressure and Hypertension Studies
article

From Blood Pressure Control to Weight-Centered Hypertension Management: The Emerging Role of Incretin-Based Therapies

Margarita Gjata, Irida Kecaj, Ergita Nelaj, Kei Xixhabesi
article en

Abstract

Obesity and hypertension often coexist in the same person and reinforce each other. Treatment of hypertension in people with obesity has been based mainly on lifestyle changes and the gradual addition of antihypertensive drugs. The development of GLP-1 receptor agonists and combined GIP/GLP-1 agonists has transformed the treatment of obesity, with implications beyond weight loss. These therapies can produce significant weight loss, but they also lower blood pressure and improve several other cardiometabolic risk factors. Recent data suggest that the reduction in blood pressure is largely related to weight loss, but is not necessarily fully explained by it. Effects on natriuresis, endothelial function, inflammation, neurohormonal activity, and circulating volume may represent additional mechanisms. In practice, this creates a new situation: a patient who loses significant weight may need less antihypertensive therapy. Our aim is to examine the relationship between obesity and hypertension, the clinical evidence on semaglutide, tirzepatide, and newer incretin-based therapies, as well as the possible transition from an approach focused solely on blood pressure ​​toward management that also addresses adiposity as part of the disease mechanism.

Acta Marisiensis. Seria Medica
Mother Teresa Hospital (AL)
Good health and well-being
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon